Compare Infosys Limited (INFY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs State Street SPDR S&P Biotech ETF — how do they compare? Infosys Limited trades at $10.74 (market cap $41.74B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: Infosys Limited is far larger — about 4.1× State Street SPDR S&P Biotech ETF's market cap, and Infosys Limited pays a 4.89% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| INFY | XBI | |
|---|---|---|
Market Cap | $41.74B | $10.11B |
Volume | 31,354,285 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $20.22 | $169.55 |
52-Week Low | $10.49 | $104.99 |
Typical Hold Time | 27 Days | 38 Days |
Enterprise Value | $39.48B | — |
Dividend Yield | 4.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.75, up 1.9% in the last 24 hours, with a bearish technical signal from moving averages. The company reported a net income of $3.16B on $19.28B revenue for 2025, with profitability metrics like a 16.37% net margin and 32.12% ROE. Recent news highlights strategic AI collaborations, such as with Columbia University and ABN Amro, to drive innovation. Earnings have been mixed, with beats in Q4 2025 and Q1 2026 but a miss in Q2 2026.
The outlook is cautious; while valuation ratios like a P/E of 13.21 appear reasonable and analyst consensus targets $11.48, weak IT spending and AI pricing pressure pose risks. Institutional sentiment is mixed with 35% buy ratings, but negative cash flow trends in 2026 forecast demand careful monitoring of execution against guidance.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
